Patients with cardiogenic shock (CS) display systemic inflammation and a high rate of infections, suggesting important immune disturbances. To explore the immune response to CS, we prospectively measured, in 24 consecutive CS patients, differential white blood cell (WBC) counts and the cytokines IL-1β, IL-5, IL-6, IL-10, TNFα, IFNγ, MCP-1 and eotaxin (CCL11), at Day 1 (T1), day 3 (T2) and day 6-8 (T3). Secondary infections and their influence on cytokines and WBCs were determined. CS induced early (T1) neutrophilia and elevated levels of IL-6, IL-10 and MCP-1, correlating with shock severity. The eosinophil chemoattractant eotaxin was elevated at T1 and decreased thereafter, and a progressive rise of blood eosinophils was noted over time. P...
BACKGROUND: Cardiogenic shock is characterised by inadequate tissue perfusion because of cardiac dy...
International audienceThe pathophysiology of cardiogenic shock (CS) varies depending on its etiology...
The IABP-SHOCK-trial was a morbidity-based randomized controlled trial in patients with infarction-r...
IntroductionPatients with cardiogenic shock (CS) are at a high risk of developing infectious complic...
We report a case of a 60-year-old man with acute myocardial infarction (AMI) treated using thromboly...
Background: Inflammatory response is an important feature of acute coronary syndromes and myocardial...
BackgroundSeptic shock (SS) and cardiogenic shock (CS) are two types of circulatory shock with a dif...
Background: Whole body ischemia and reperfusion injury after cardiac arrest leads to the massive inf...
AbstractObjectivesPeripheral blood parameters implicating the irreversible damages of cardiogenic sh...
Cardiogenic shock (CS) is the final common pathway of impaired cardiovascular performance that resul...
International audienceAims: Optimal outcome after cardiogenic shock (CS) depends on a coordinated he...
International audienceBACKGROUND: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) provide...
Cardiogenic shock (CS) is theleading cause of death for pa-tients with acute myocardial infarction (...
Abstract: Cardiogenic shock (CS) is the most common cause of death in hospitalized patients with acu...
Aims: Data on cardiogenic shock (CS) in autoimmune diseases (AID) is limited. Our study aims to eva...
BACKGROUND: Cardiogenic shock is characterised by inadequate tissue perfusion because of cardiac dy...
International audienceThe pathophysiology of cardiogenic shock (CS) varies depending on its etiology...
The IABP-SHOCK-trial was a morbidity-based randomized controlled trial in patients with infarction-r...
IntroductionPatients with cardiogenic shock (CS) are at a high risk of developing infectious complic...
We report a case of a 60-year-old man with acute myocardial infarction (AMI) treated using thromboly...
Background: Inflammatory response is an important feature of acute coronary syndromes and myocardial...
BackgroundSeptic shock (SS) and cardiogenic shock (CS) are two types of circulatory shock with a dif...
Background: Whole body ischemia and reperfusion injury after cardiac arrest leads to the massive inf...
AbstractObjectivesPeripheral blood parameters implicating the irreversible damages of cardiogenic sh...
Cardiogenic shock (CS) is the final common pathway of impaired cardiovascular performance that resul...
International audienceAims: Optimal outcome after cardiogenic shock (CS) depends on a coordinated he...
International audienceBACKGROUND: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) provide...
Cardiogenic shock (CS) is theleading cause of death for pa-tients with acute myocardial infarction (...
Abstract: Cardiogenic shock (CS) is the most common cause of death in hospitalized patients with acu...
Aims: Data on cardiogenic shock (CS) in autoimmune diseases (AID) is limited. Our study aims to eva...
BACKGROUND: Cardiogenic shock is characterised by inadequate tissue perfusion because of cardiac dy...
International audienceThe pathophysiology of cardiogenic shock (CS) varies depending on its etiology...
The IABP-SHOCK-trial was a morbidity-based randomized controlled trial in patients with infarction-r...